Medical Management of Pituitary-Dependent Hyperadrenocorticism: Mitotane versus Trilostane
- 1 February 2007
- journal article
- review article
- Published by Elsevier in Clinical Techniques in Small Animal Practice
- Vol. 22 (1) , 18-25
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Effect of trilostane on serum concentrations of aldosterone, cortisol, and potassium in dogs with pituitary-dependent hyperadrenocorticismAmerican Journal of Veterinary Research, 2004
- Adrenal necrosis in a dog receiving trilostane for the treatment of hyperadrenocorticismJournal of Small Animal Practice, 2004
- Trilostane treatment in dogs with pituitary‐dependent hyperadreno‐corticismAustralian Veterinary Journal, 2003
- Investigation of the role of aldosterone in hypertension associated with spontaneous pituitary‐dependent hyperadrenocorticism in dogsJournal of Small Animal Practice, 2002
- Trilostane treatment of 78 dogs with pituitary‐dependent hyperadrenocorticismVeterinary Record, 2002
- Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostaneAmerican Journal of Veterinary Research, 2002
- Medical Treatment of Canine Pituitary-Dependent Hyperadrenocorticism (Cushing's Disease)Veterinary Clinics of North America: Small Animal Practice, 2001
- Retrospective Evaluation of Urinary Tract Infection in 42 Dogs with Hyperadrenocorticism or Diabetes Mellitus or BothJournal of Veterinary Internal Medicine, 1999
- Results of non‐selective adrenocorticolysis by O,p'‐DDD in 129 dogs with pituitary‐dependent hyperadrenocorticismVeterinary Record, 1999
- Mitotane (o, p‘-DDD) Treatment of 200 Dogs with Pituitary-Dependent HyperadrenocorticismJournal of Veterinary Internal Medicine, 1991